This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Discussing the recent FDA approval of LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy.
Ticker(s): AVDLWho's the expert?
- Board certified in both neurology and sleep medicine, and he is the founder and CEO of Tricoastal Narcolepsy and Sleep Disorders Center.
- Currently manages around 200-250 patients with cataplexy and narcolepsy, and 15 patients with idiopathic hypersomnia.
- Extensive expertise in the treatment of narcolepsy, obstructive sleep apnea (OSA), and insomnia. He is published in peer-reviewed journals and texts, as well as online media.
- Previously served as principal investigator in clinical research trials focused on narcolepsy and OSA.
Interview GoalTo discuss the recent FDA approval and published literature on Avadel's LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
